Sonavex, Inc. announced today the final closure of its expanded $4.5M Series A and filing of a 510(k) submission to the U.S. Food and Drug Administration (FDA) for its EchoMark device. The proceeds will accelerate Sonavex’s commercial launch later this year and support further product development. Participants in the additional financing included Fusion Fund (aka NewGen Capital), FundRx, and existing investors.